Onconetix Expands Executive Leadership, Adding David White As CEO And Sammy Dorf To Its Board Of Directors

Onconetix, Inc. announced important leadership changes as the company moves ahead with its previously announced plan to acquire Realbotix LLC, a developer of advanced AI-driven humanoid robots. The company has appointed David White as its new Chief Executive Officer, effective March 18, 2026. In addition, Sammy Dorf will be joining the Board of Directors and serving on the Audit Committee starting March 19, 2026. Karina Fedasz, who has been serving as the Interim Chief Executive Officer, will continue in her role as the Interim Chief Financial Officer.

David White joins Onconetix with more than 30 years of leadership experience across several industries, including transportation, healthcare, and manufacturing. Over the course of his career, he has worked in key executive roles such as CEO, CFO, and COO. He previously served as CEO of American Student Transportation Partners and TransCare Inc., and has held board positions with various public companies. His board experience includes serving as an independent director and Audit Committee Chair for both a NYSE American-listed company and a TSX-listed global equipment manufacturer. He currently serves as an independent director at Art’s Way Manufacturing, Inc., a Nasdaq-listed company. White holds a Bachelor of Arts from the University of Western Ontario and an MBA from the University of Toronto, and he is also a Chartered Professional Accountant.

In his statement, White expressed his enthusiasm about joining Onconetix at a time when the company is preparing for a major transition. He noted that the pending acquisition of Realbotix offers a significant opportunity to build a forward-looking business that combines artificial intelligence with humanoid robotics, an area he expects will continue to grow rapidly. He added that his main focus will be ensuring the successful completion of the transaction while helping position the combined company for long-term, sustainable growth.

The company also announced the appointment of Sammy Dorf to the Board of Directors. Dorf is an entrepreneur, investor, and experienced public company director with a strong background in helping companies grow in both regulated and emerging markets. He co-founded Verano Holdings Corp. in 2015 and played a major role in expanding the business and taking it public in 2021. After leaving Verano in 2023, he founded Dreamlife Consulting, where he advises companies on raising capital and developing growth strategies. He later became a partner at Blue Current, LLC, a retail real estate investment firm. Dorf also has experience serving in important board positions, including as Executive Chairman of Flora Growth Corp. from December 2024 to September 2025. He currently serves on the board of SRx Health Solutions, where he is Co-Chair of the Governance Committee and a member of the Audit Committee, and he is also on the board of Cube Exchange, a digital asset platform working toward a public listing.

In his remarks, Dorf said he is excited to join the Board at a time when Onconetix is working to complete the acquisition of Realbotix. He said he has always focused on identifying companies with strong technology and the ability to scale, and he believes Realbotix fits that profile well. Dorf added that the humanoid robotics industry is expanding quickly and that this transaction gives Onconetix shareholders an opportunity to benefit from the sector’s growth. He also expressed his intention to contribute his experience in capital markets and strategic planning to support the company’s next steps.

Andrew J. Oakley, Chairman of the Board at Onconetix, said the company is pleased to welcome both David White and Sammy Dorf at such an important point in its development. He noted that White’s extensive executive and financial background, combined with Dorf’s experience in scaling companies and navigating the capital markets, will strengthen the company’s leadership. Oakley added that as Onconetix continues to advance the agreement to acquire Realbotix, the Board and management team are well-prepared to guide the company through this process and pursue the opportunities ahead.